ABSTRACT OF THE DISCLOSURE

Please add new page 35 to the application containing the abstract of the disclosure as follows:

(35)

ABSTRACT OF THE DISCLOSURE

A serine protease inhibitor having the formula (I),



in which

J is H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;

W is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-$CH((CH_2)_qC(O)OR^1)$-C(O)-, -NR^4-$CH((CH_2)_qC(O)N(R^{2a},R^{2b}))$-C(O)-, -$NR^4$-$CH((CH_2)_qC(O)Het)$-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq, D-3 Piq, glutanyl or a (C_1-C_6) alkylester thereof;

E is -NR^2-CH_2- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected form (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or halogen, and from (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2, R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl,

(3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is the same as R^2 or is Het-(1-6C)alkyl;

R^4 is H or (1-3C)alkyl;

X and Y are CH or N, with the proviso that they are not both N;

Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S;

m is 1 or 2;

p is 1, 2 or 3;

q is 1, 2 or 3;

t is 2, 3 or 4;

or a pharmaceutically acceptable addition salt or solvate thereof.